Edge Therapeutics - EDGE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.62
▼ -0.08 (-2.16%)
Get New Edge Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDGE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Edge Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.62.

This chart shows the closing price for EDGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Edge Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018Credit Suisse GroupDowngradeOutperform ➝ Underperform$17.00High
3/28/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$17.00High
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/10/2022
  • 3 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/9/2022
  • 0 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/9/2022
  • 0 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
6/8/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
7/8/2022
  • 10 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/7/2022
  • 7 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/6/2022
  • 5 very positive mentions
  • 37 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
10/6/2022

Current Sentiment

  • 5 very positive mentions
  • 37 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Edge Therapeutics logo
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.
Read More

Today's Range

Now: $3.62
Low: $3.45
High: $3.75

50 Day Range

MA: $4.11
Low: $0.50
High: $6.71

52 Week Range

Now: $3.62
Low: $0.28
High: $17.38

Volume

321,964 shs

Average Volume

373,201 shs

Market Capitalization

$114.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Edge Therapeutics?

The following sell-side analysts have issued stock ratings on Edge Therapeutics in the last year:
View the latest analyst ratings for EDGE.

What is the current price target for Edge Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Edge Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Edge Therapeutics in the next year.
View the latest price targets for EDGE.

What is the current consensus analyst rating for Edge Therapeutics?

Edge Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EDGE.

What other companies compete with Edge Therapeutics?

How do I contact Edge Therapeutics' investor relations team?

Edge Therapeutics' physical mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company's listed phone number is (800) 208-3343 and its investor relations email address is [email protected] The official website for Edge Therapeutics is www.edgetherapeutics.com. Learn More about contacing Edge Therapeutics investor relations.